The evidence base supporting the therapeutic rationale for using GLP-1/GIP receptor agonists in Type 1 Diabetes (T1D) with overweight or obesity has both strengths and weaknesses
Improved wound healing, reduced inflammation, reduced hepatic fat content, decreased infarct size following myocardial infarction or intracranial stroke, improved vascular function with decreased oxidative stress, improved endothelial dysfunction, and lowering of albuminuria have also been observed in pre-clinical studies [24]
This includes people with a personal or family history of medullary thyroid carcinoma, a rare form of thyroid cancer
Patients with coexisting diabetes or obesity and Crohn's disease require careful coordination between specialists, as GLP-1 agonists' gastrointestinal side effects overlap significantly with IBD symptoms, potentially complicating disease monitoring and management
Healthcare providers can offer guidance on dosing strategies to mitigate side effects while maintaining the efficacy of the medication.
A smaller group reports headaches or nausea if taken without food
